Apellis Pharmaceuticals

$46.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.10 (+2.44%) As of 3:36 PM UTC today

Why Robinhood?

You can buy or sell APLS and other stocks, options, and ETFs commission-free!

About APLS

Apellis Pharmaceuticals, Inc. Common Stock, also called Apellis Pharmaceuticals, is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA. The listed name for APLS is Apellis Pharmaceuticals, Inc. Common Stock.

CEO
Cedric Francois
Employees
235
Headquarters
Waltham, Massachusetts
Founded
2009
Market Cap
3.65B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
507.83K
High Today
$48.34
Low Today
$45.44
Open Price
$45.93
Volume
74.02K
52 Week High
$58.47
52 Week Low
$16.85

APLS Earnings

-$2.29
-$1.22
-$0.14
$0.93
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
$0.93 per share
Replay Earnings Call

You May Also Like

SITM
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure